Physician profile
Michelle L Wilson
NPI 1932129822
$13,565.97
in general payments reported to CMS, 2019-2025
58 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $1,075 · 2021: $1,535 · 2022: $2,572 · 2023: $2,555 · 2024: $2,469 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,010.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,010.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,754.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,495.92 | 2019-2025 | |
| Lilly USA, LLC | $1,255.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,091.84 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $895.54 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $701.58 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.52 | 2019-2025 | Ofev, Jardiance |
| Novartis Pharmaceuticals Corporation | $350.39 | 2019-2025 | |
| Glaxosmithkline, LLC. | $337.35 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $327.22 | 2019-2024 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $323.25 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $318.00 | 2019-2023 | |
| Astellas Pharma US INC | $289.81 | 2019-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $283.27 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.76 | 2019-2025 | Xifaxan, Trulance |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.